The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Hi Kong1, yes, there is reason to believe that instead of 3 weeks between dosings (as for standard dox) that ava6k could be given with a shorter interval. This is because patient may not need so much time to recover.
However, this is not something that they would change in P1a, and unlikely in P1b. This is something that may be experimented with in P2, or in an entirely different trial after approval. As BV has noted, follow up trials of ava6k on different tumor types will be necessary to get approval for those types. So further trials are definitely in the pipeline. Also note that most of those trials don't need to start with P1a...but rather can be jumped in at P1b or P2.
From the RNS on the initial results of the lateral flow: "These data from the first clinical studies will allow us to quickly progress with confidence into the full clinical validation of the test, MANUFACTURED AT SCALE, at our clinical trial sites in the UK and the EU. I am confident that these data will accelerate our commercial discussions regarding the roll-out of the test when it is approved for professional use."
emphasis mine. I remember some discussion here last autumn (and in the presentations around that time) that the final clinical validation needed to be done in the same way that the tests will be manufactured, i.e. the final version, and using the completed assembly line. So they are already pumping out loads of the mofos. But the question is, do you hit the button and produce millions before final CV, expecting excellent results and have a 3-4 week stockpile, or do you only produce the few thousands needed for the CV? I guess that depends on how much risk the gvmt is willing to cover (as I'd be suprised if the companies themselves would take such a risk, financially).
From the update: "This evaluation is expected to continue for another two or three weeks and the Group is establishing outsourced manufacturing capacity for the BAMS tests in collaboration with Adeptrix so that it is in a position to formally validate the diagnostic product as soon as possible. Avacta is also in discussions with a large commercial partner to provide a route to market for the BAMS assay."
Alright, I'll throw in some wild speculation. I say 20-30% rise on Monday morning, followed by a ~100% rise following the announcement by BoJo and/or RSN Tuesday morning. This will then be followed by a sustained rise over the coming weeks as news of the contract amounts and manufacturers are announced. Then we'll see another big rise when the US announce that Abakta are their saviour. By the end of March, we'll be at 7 quid. But then, oh and then, we'll start hearing about world-wide manufacturing and the scope of the situation will begin to be clear. Then we're looking at 15 quid+ by the end of April, and finally a steady rise until we get the AVA6000 first results. What am I basing this on, you ask? Wild speculation. But now, if I'm anywhere near what actually happens, I'll claim genius foresight. And if not, no one will remember this anyway...
Senor Smith normally has a hard-hitting interview with Giles (sweating bullets) to highlight each RNS. Two straight now without. No trading update as well. Almost seems like they might be sitting on some news to be released imminently.
good point CS. I've felt for a while that perhaps the better way to go for Avacta would have been to licence out the affimers to Roche or Abbot Labs or another big player and let them handle the development and manufacturing. But you're point stands, maybe that wouldn't have accelerated much. I'm still disappointed that BBI are helping develop/manufacture/TT three antigen tests, as I fear that spreads them too thin, it would have been better to do one at a time, most likely. But that's out of Avacta's hands.
ndeed, things have gone quiet on that front recently. Looking at the RNSs of Deepverge, this technology is still in the testing phase…so it’s not just Avacta who are suffering from the painfully slow testing process. I see that Deepverge have an investers meeting next week (Dec. 1st)…perhaps we’ll get more updates then (although the description emphasises looking ‘beyond covid’).
Sorry, but CRISPR is not another covid testing technqiue, it is a gene editting technique. In fact, its inventors won the Noble Prize for Chemistry for it this year. So this seems to have nothing to do with Avacta.